Viriom Inc. is advancing breakthrough medicines that are effective and affordable with the ultimate goal of curing HIV, chronic HBV and respiratory infections in both developing and developed countries.

Avelas is a clinical-stage
drug-device company focused on developing and commercializing pegloprastide with the goal of revolutionizing cancer surgery with real-time margin detection.

Chromis Therapeutics focuses on the development of curative treatments for chronic HBV (Hepatitis B virus) infection, based on its advanced proprietary drug design and discovery platform.

i2020 helps accelerate early stage drug discovery platforms towards advanced lead
and clinical candidate level within a two-year time framework.

Leap is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 protein.

Afraxis' patented ESP
(Enhanced Spine Profiling) technology produces rapid, high-information read-outs of synaptic networks from in-vivo/in-vitro/ex-vivo preparations.

Vaxxas focuses on enhancing the performance of vaccines with its HD-MAP technology platform, which rapidly delivers vaccine to the abundant immune cells immediately below the skin surface.

Context Therapeutics Inc.,
is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast
and gynecological
cancers.